X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA FDC LTD. ALEMBIC PHARMA/
FDC LTD.
 
P/E (TTM) x 16.5 16.2 101.7% View Chart
P/BV x 3.6 2.2 165.0% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 ALEMBIC PHARMA   FDC LTD.
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
FDC LTD.
Mar-18
ALEMBIC PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs664319 208.2%   
Low Rs412164 251.5%   
Sales per share (Unadj.) Rs208.761.6 338.6%  
Earnings per share (Unadj.) Rs31.09.9 311.6%  
Cash flow per share (Unadj.) Rs37.112.0 310.2%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.273.2 197.1%  
Shares outstanding (eoy) m188.52174.40 108.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.63.9 65.8%   
Avg P/E ratio x17.424.3 71.5%  
P/CF ratio (eoy) x14.520.2 71.8%  
Price / Book Value ratio x3.73.3 113.1%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,46142,118 240.9%   
No. of employees `000NA5.5 0.0%   
Total wages/salary Rs m7,4672,167 344.6%   
Avg. sales/employee Rs ThNM1,943.7-  
Avg. wages/employee Rs ThNM391.7-  
Avg. net profit/employee Rs ThNM313.7-  
INCOME DATA
Net Sales Rs m39,34710,751 366.0%  
Other income Rs m94510 18.4%   
Total revenues Rs m39,44111,260 350.3%   
Gross profit Rs m8,7362,267 385.4%  
Depreciation Rs m1,152351 327.9%   
Interest Rs m18414 1,315.0%   
Profit before tax Rs m7,4932,411 310.8%   
Minority Interest Rs m11-5 -225.0%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568671 233.5%   
Profit after tax Rs m5,8441,735 336.8%  
Gross profit margin %22.221.1 105.3%  
Effective tax rate %20.927.8 75.1%   
Net profit margin %14.916.1 92.0%  
BALANCE SHEET DATA
Current assets Rs m19,5777,213 271.4%   
Current liabilities Rs m14,8962,104 708.1%   
Net working cap to sales %11.947.5 25.0%  
Current ratio x1.33.4 38.3%  
Inventory Days Days9054 164.7%  
Debtors Days Days4528 163.6%  
Net fixed assets Rs m27,0976,865 394.7%   
Share capital Rs m377175 215.2%   
"Free" reserves Rs m26,81112,586 213.0%   
Net worth Rs m27,18812,761 213.1%   
Long term debt Rs m4,9936 83,216.7%   
Total assets Rs m47,77815,041 317.6%  
Interest coverage x41.7173.2 24.1%   
Debt to equity ratio x0.20 39,058.7%  
Sales to assets ratio x0.80.7 115.2%   
Return on assets %12.611.6 108.5%  
Return on equity %21.513.6 158.1%  
Return on capital %23.619.0 124.5%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4531,889 1,029.9%   
Fx outflow Rs m6,0650-   
Net fx Rs m13,3881,889 708.8%   
CASH FLOW
From Operations Rs m8,1201,498 541.9%  
From Investments Rs m-7,556201 -3,757.3%  
From Financial Activity Rs m590-1,694 -34.8%  
Net Cashflow Rs m1,15310 11,197.1%  

Share Holding

Indian Promoters % 74.1 68.9 107.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 4.7 61.7%  
FIIs % 9.1 7.5 121.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 19.0 73.2%  
Shareholders   49,328 23,730 207.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SHASUN PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

FDC LTD. Announces Quarterly Results (3QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Feb 15, 2019 | Updated on Feb 15, 2019

For the quarter ended December 2018, FDC LTD. has posted a net profit of Rs 437 m (up 2.5% YoY). Sales on the other hand came in at Rs 3 bn (up 1.4% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - NATCO PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS